FOLR1 and ovarian cancer: FR-targeted liposomes containing a combination of niraparib and doxorubicin were tested in a panel of ovarian cancer cell lines, including OVCAR8 (FRα-overexpressing) and HEYA8 (FRα non-overexpressing).